All In Biotech

Drug Trial Radar · NCT07011056

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

A Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Jul 18, 2025

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Sponsor type
Industry
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate the differences in objective response rate and overall survival between the Purinostat mesylate for injection and selinexor, as assessed by blinded independent central review (BICR), in patients with relapsed or refractory diffuse large B-cell lymphoma. .The participants in the experimental group will receive treatment with Purinostat mesylate for injection. The dosage is 11.2 mg/m2. Each administration cycle consists of intravenous administration on days 1, 4, 8, and 11. A 21-day period constitutes one treatment cycle, and the total treatment cycle lasts for 6 cycles. .Participants in the control group will receive selinexor treatment. The recommended dose is 60 mg per dose, taken orally on days 1 and 3 of each week (for example, Monday and Wednesday, or Tuesday and Thursday), and a 4-week period constitutes one treatment cycle.

Conditions

  • Recurrent and Refractory Diffuse Large B-cell Lymphoma

Interventions

  • Purinostat Mesylate for InjectionDrug

    The subjects in the experimental group will receive treatment with Purinostat Mesylate for injection. The dosage is 11.2 mg/m2. Each administration cycle consists of intravenous infusion on days 1, 4, 8, and 11. The administration cycle lasts for 21 days, and the total treatment cycle is 6 cycles. After 6 cycles, the investigator will assess whether the subjects can continue to benefit, whether they can sustain the treatment with the investigational drug, and adjust the frequency of continuous administration based on the evaluation results of the efficacy over these 6 cycles.

  • Selinexor TabletsDrug

    The recommended dose of selinexor tablets is 60 mg per administration, taken orally on the 1st and 3rd day of each week (for example, Monday and Wednesday, or Tuesday and Thursday), with a 4-week course as one treatment cycle. Patients who achieve partial response (judged by the investigator as the best expected response for the subject) or have better efficacy can switch to maintenance treatment, with a maintenance dose of 60 mg taken orally once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Overall SurvivalTime frame: week 96

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.